Compare Aehr Test Systems (AEHR) vs Baxter International Inc (BAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs Baxter International Inc — how do they compare? Aehr Test Systems trades at $67.9 (market cap $2.11B), while Baxter International Inc trades at $21.93 (market cap $11.81B). The key difference: Baxter International Inc is far larger — about 5.6× Aehr Test Systems's market cap, and Baxter International Inc pays a 0.87% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | BAX | |
|---|---|---|
Market Cap | $2.11B | $11.81B |
Sector | Technology | Health |
52-Week High | $116.58 | $30.66 |
52-Week Low | $13.29 | $15.80 |
Enterprise Value | $2.08B | $19.48B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.
Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
